Contract 36F79722D0063
Mylan Specialty Lp · Department Of Veterans Affairs · August 29, 2024
Mylan Specialty Lp was awarded a federal contract by Department Of Veterans Affairs on August 29, 2024 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 22 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 24, 2026. If all options are exercised, the contract could reach $514.85 million.
Contract details
- PIID
- 36F79722D0063
- Award type
- Fss
- Pricing
- Fixed Price With Economic Price Adjustment
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- August 29, 2024
- Latest action
- March 24, 2026
Description
65IB - ADMINISTRATIVE CHANGES - CONTACT FOR CONTRACT ADMINISTRATION & SIGNATORY AUTHORITY FORM CHANGES
Modification timeline
-
March 24, 2026Mod P00078 · Other Administrative Action$0
-
March 10, 2026Mod P00077 · Supplemental Agreement For Work Within Scope65IB: SIN 42-2A - NDC NUMBER CHANGE$0
-
March 4, 2026Mod P00076 · Supplemental Agreement For Work Within ScopeTO UPDATE EMAIL ADDRESS IN NAC-CM$0
-
March 3, 2026Mod P00075 · Supplemental Agreement For Work Within Scope65IB - SIN 42-2A - PRODUCT DELETION - DISCONTINUED MANUFACTURING AND STOCK COMPLETELY EXHAUSTED$0
-
March 2, 2026Mod P00074 · Supplemental Agreement For Work Within Scope65IB: SIN 42-2A - NDC NUMBER CHANGE$0
-
January 30, 2026Mod P00073 · Add Subcontracting PlanAPPROVED SUBCONTRACTING PLAN FOR 2026$0
-
January 15, 2026Mod P00071 · Supplemental Agreement For Work Within ScopeFSS$0
-
January 14, 2026Mod P00072 · Other Administrative Action65IB - 42-2A ADMINISTRATIVE CHANGE - NAC-CM DATABASE CORRECTION$0
-
January 13, 2026Mod P00070 · Supplemental Agreement For Work Within ScopeFSS$0
-
December 15, 2025Mod P00069 · Supplemental Agreement For Work Within Scope65 I B, SIN 42-2A - VOLUNTARY TEMPORARY PRICE REDUCTIONS - SPECIFIC BIG 4 NDCS & ALL OGA USERS$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36F79722D0063?
Contract 36F79722D0063 is a federal contract awarded to Mylan Specialty Lp by Department Of Veterans Affairs on August 29, 2024 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 22 times since the base award.
Who won contract 36F79722D0063?
Mylan Specialty Lp won contract 36F79722D0063 from Department Of Veterans Affairs.
How much is contract 36F79722D0063 worth?
Contract 36F79722D0063 has obligated $0 to date but carries a potential ceiling of $514.85 million if fully funded and all options are exercised.